Results 221 to 230 of about 192,797 (347)

Comparative effectiveness and safety of different progestins in combined oral contraceptives: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

Arch Gynecol Obstet
Li B, Xu X, Xu K, Ni J, Wang C, Zhang T.
europepmc   +1 more source

Comparison of Combined Oral Contraceptives and a Transdermal Estrogen Patch With Oral Progesterone: Treatment of Abnormal Uterine Bleeding in Adolescents. [PDF]

Cureus
Ulukapi HB, Simsek E.
europepmc   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source

Experts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4). [PDF]

Front Glob Womens Health
Creinin MD, Cagnacci A, Spaczyński RZ, Stute P, Chabbert-Buffet N, Korver T, Simoncini T.   +6 more
europepmc   +1 more source

Long‐Term Control of Human Papillomavirus‐Related Focal Epithelial Hyperplasia in an Human Immunodeficiency Virus‐Positive Patient Using Methylene Blue‐Mediated Photodynamic Therapy. A Case Report

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Background Human papillomavirus (HPV) infections are a major cause of oral lesions, and in individuals living with HIV, lesions such as focal epithelial hyperplasia (FEH) may persist or exhibit atypical features, potentially progressing to more severe conditions if untreated.
Juliana Cristina Oliverio de Araújo, Hermano Camelo Paiva, Paula Margarida Meyer Faara, Og Fray Junior, Martha Simões Ribeiro   +4 more
wiley   +1 more source

Incidence rate of venous thrombosis in women switching combined oral contraceptives: a cohort study. [PDF]

Res Pract Thromb Haemost
Khialani D, de Rooij E, Szépligeti SK, Dudukina E, le Cessie S, Ehrenstein V, Rosendaal FR, van Hylckama Vlieg A.   +7 more
europepmc   +1 more source

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. [PDF]

Br J Haematol, 2020
Khialani D, le Cessie S, Lijfering WM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A.   +5 more
europepmc   +1 more source

The Pill and Cancer [PDF]

, 1985
Hume, Kevin
core   +1 more source

Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy‐Based Device Treatments: A Systematic Review and Network Meta‐Analysis

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Background Postinflammatory hyperpigmentation (PIH) is the most common adverse effect following laser treatments, yet the relative efficacy of proposed prophylactic measures remains uncertain. Objectives To compare the effectiveness of available interventions for preventing laser‐induced PIH in randomized controlled trials (RCTs).
Supisara Wongdama, Sasitorn Yenyuwadee, Jayne Bernadeth Li, Surasak Saokaew, Sukrit Kanchanasurakit, Woraphong Manuskiatti   +5 more
wiley   +1 more source

Thrombomodulin is a stronger indicator of combined oral contraceptives-induced activated protein C pathway resistance in the thrombin generation test than activated protein C. [PDF]

Front Cardiovasc Med
Ninivaggi M, Sokolova L, Donkervoort D, de Laat B, de Laat-Kremers R.   +4 more
europepmc   +1 more source